Litcius/Paper detail

Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1

Julien Rossignol, Zakia Belaid, Guillemette Fouquet, Flavia Guillem, Rachel Rignault, Pierre Milpied, Amédée Renand, Téreza Coman, Maud D’Aveni, Michaël Dussiot, Elia Colin, Jonathan Lévy, Caroline Carvalho, Nicolas Goudin, Nicolas Cagnard, Francine Côté, Joël Babdor, Kanit Bhukhai, Laura Polivka, Amélie Bigorgne, Heloise M. Halse, Aurélien Marabelle, Séverine Mouraud, Yves Lepelletier, Thiago Trovati Maciel, Marie‐Thérèse Rubio, Delphine Héron, Caroline Robert, Isabelle Girault, Doris Lebeherec, Jean‐Yves Scoazec, Ivan Cruz Moura, Louise Condon, Mirjana Weimershaus, Franck Pagès, Jean Davoust, David‐Alexandre Gross, Olivier Hermine

2022iScience12 citationsDOIOpen Access PDF

Abstract

T cells predicts poor outcome of patients treated with anti-PD1. NRP1 is a promising target to overcome resistance to anti-PD1 therapies.

Topics & Concepts

Immune systemNeuropilin 1Cytotoxic T cellCancer researchCD8Immune checkpointImmunologyImmunotherapyBiologyMedicineIn vitroVascular endothelial growth factorVEGF receptorsBiochemistryAngiogenesis and VEGF in CancerCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune Response
Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1 | Litcius